*Ruixiang Li^1,2,3, Teppi Matsui¹, Aya Ito-Ishida³ (1. Graduate School for Brain Science, Doshisha University, Kyoto, Japan, 2. Organization for Research Initiatives and Development, Doshisha University, Kyoto, Japan, 3. RIKEN Center for Brain Science)

*Mayuko Takano^1,2, Masataka Wada^1,3, Shinichiro Nakajima¹, Yu Mimura¹, Keita Taniguchi¹, Shiori Honda^1,4, Hiroyuki Uchida¹, Masaru Mimura¹, Yoshihiro Noda^1,5 (1. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan, 2. TEIJIN PHARMA LIMITED, Tokyo, Japan, 3. Department of Psychiatry and Behavioral Sciences, Stanford University, CA, USA, 4. Graduate School of Media and Governance, Keio University, Kanagawa, Japan, 5. Department of Psychiatry, International University of Health and Welfare, Mita Hospital, Tokyo, Japan)

*Yumina Nakane^1,2, Shiori Honda^1,3, Hideaki Yasuda⁴, Hideaki Tani¹, Masataka Wada^1,5, Takahide Etani¹, Yoshito Saito⁶, Marie Kitano^7,8, Lisa Harada¹, Ryoma Kani⁹, Ken Araki¹, Einosuke Ono¹, Moriyama Sotaro¹, Koki Takahashi¹, Rina Ishimaru¹, Akihiko Miura, Shintaro Asada, Sunjun Huh¹⁰, Hiroyuki Uchida¹, Shinichiro Nakajima¹ (1. Department of Neuropsychiatry, Keio University, School of Medicine , 2. Department of Psychiatry, Yamanashi prefectural kita hospital , 3. Graduate School of Media and Governance, Keio University, 4. Department of Psychiatry, Sekito Hospital, 5. Department of Psychiatry and Behavioral Sciences, Stanford University, USA, 6. Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Australia, 7. Psychiatry, Monash Medical Centre, Australia , 8. Department of Psychiatry, University of Melbourne, Australia , 9. Postgraduate Education Center Kameda Medical Center , 10. Keio University School of Medicine)